A Turning Point in HER2-Mutated NSCLC: What Clinicians Need to Know Now

36 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join us for this dynamic 15-minute interactive social media event featuring Drs Eric Singhi and Heather Wakelee as they dive into the rapidly evolving landscape of HER2-mutated non-small cell lung cancer (NSCLC). This fast-paced program delivers cutting-edge clinical insights designed to immediately impact your practice. Our expert faculty will guide you through the latest breakthrough data on emerging and established therapies, exploring key trial results, mechanisms of action, and real-world applications. You'll gain practical knowledge on optimizing biomarker testing strategies, navigating current guidelines, and integrating new evidence into patient care decisions. Timed strategically around major data releases, this activity ensures you stay at the forefront of HER2-mutated NSCLC management. The interactive Q&A session provides direct access to expert perspectives on your most pressing clinical questions. Transform your approach to HER2-mutated NSCLC. Join the conversation that's shaping the future of precision oncology.

Faculty: Eric K. Singhi, MD
Faculty: Heather Wakelee, MD

Earn free 0.25 AMA PRA Category 1 Credit™, 0.25
ANCC Contact Hour(s) (0.00 contact hours are in the area of pharmacology), and 0.25
Knowledge-based ACPE (0.025 CEUs). Access for credit will be shared at the end of this live event.

Click the link to view the Accreditation and Disclosure details before participating:
https://www.medscape.org/s/viewarticle/turning-point-her2-mutated-nsclc-what-clinicians-need-know-2025a1000mzi

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Categoria
Oncology
Commenta per primo questo video.

Prossimo